Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE007 (JPN) (Dr. Dubois)
· consented 2023-03-29
Adverse events
5
Serious AEs
0
Open data queries
0
Luna dropout signal
–
Adverse events
moderate
assessed
2026-08-18
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 2); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 2); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 2); relationship: N
mild
assessed
2026-08-18
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 2); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 2); relationship: Y
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.